Product category:
Genomics
News Release from: Xantos Biomedicine
Edited by the Laboratorytalk Editorial
Team on 08 June 2004
Collaboration in histology-based target
validation
Applied Phenomics will provide Xantos with its methodological base and clinical genomics resources for validation of novel targets identified using cell-based screening approach
Xantos Biomedicine, a functional biology and drug discovery company based in Munich, Germany, and Applied Phenomics, a privately-held clinical genomics company based in Tartu, Estonia, have announced that Applied Phenomics will provide Xantos with its methodological base and clinical genomics resources for validation of novel targets identified using Xantos cell-based screening approach Xantos uses its Xantoscreen technology to discover and functionally validate novel targets on a genome-wide basis
This article was originally published on Laboratorytalk on 21 Nov 2003 at 8.00am (UK)
Related stories
Enabling functional genome-wide drug discovery
Collection of full-length human cDNA clones in mammalian expression vectors to expaned to 35,000, representing one of the world's largest collections
Screening for a protein with therapeutic relevance
Xantos will identify candidate proteins and analyse their mode of action by combining high throughput and automated overexpression of a human full-length cDNA library with an appropriate assay
For further validation of these targets on clinical samples access to high-quality and flexible set of services offered by Applied Phenomics is of key importance.
In the framework of the collaboration, Applied Phenomics uses its Phenomax tissue arrays for optimisation of anti-target immunostaining in normal tissues, and performs target immunolocalisation in tumour samples under optimised conditions.
These studies are complemented with in situ hybridisation studies and interpreted in the context of immunostainings with selected diagnostic antibodies from Applied Phenomics stock.
"Xantos focuses on the development of novel therapeutic proteins and drugs in the field of cancer and metabolic diseases.
"Validation of our novel targets in well documented clinical samples is of importance for us.
"Together with Applied Phenomics we work out detailed project procedures and we are very satisfied with the care they took to generate the data.
"Their in-depth knowledge of target validation by histological methods effectively supports our development process." stated Ulrich Brinkmann, CSO at Xantos Biomedicine.
"Our combination of state-of-the-art molecular biology and clinical pathology expertise and research-grade ethically sound tissue samples forms a solid basis for validation of targets identified in in vitro screens" stated Tambet Teesalu, CEO at Applied Phenomics.
"We are very pleased to be working with Xantos and contribute to the success of their drug development programmes".
• Xantos Biomedicine: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
